A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

ID Number 13-1046

Principal Investigator(s)
Alla Keyzner

Department(s) or Division(s)
Hematology and Medical Oncology

The purpose of this study is to compare the effects, good and/or bad of three drug combinations. The first combination is the standard treatment of daunorubicin plus AraC. This is called β€œ7+3” treatment. The second combination is another standard treatment of idarubicin plus AraC. This is called β€œIA” treatment. Both of these treatments have been approved for your cancer. The third combination will add the drug vorinostat to the standard IA therapy. Vorinostat is approved for other types of cancer, but has not been approved for your type of cancer, so it is considered investigational for this study. We want to compare the effects of these three treatments on your type of cancer.


Contact Information
Christine Woo
(212) 824-7309

Recruiting Patients: Yes